Trial · Interventional

Not yet recruitingNot applicableRegistry data

Yeast Protein Supplementation and Muscle Preservation During GLP-1RA-Induced Weight Loss

NCTNCT07817823Other idSQ202699

Open at ClinicalTrials.govAsk about this trial

This trial does not test a peptide that PepBank tracks.

Names Glucagon, does not test it. It appears in the title.

Overview

Status: Not yet recruiting
Phase: Not applicable
Enrollment: 200 participants (estimated)
Sponsor: Huazhong University of Science and Technology · Other
Design: Randomized · Quadruple masking
Countries: 1 country
China
Start: 20 Sept 2026 (estimated)
Primary completion: 30 Mar 2027 (estimated)
Completion: 30 May 2027 (estimated)
First posted: 14 Sept 2026
Last update posted: 15 Oct 2026
Conditions: Overweight and Obesity in Adults Receiving GLP-1RA Treatment

Timeline

1 trial · 1 not yet recruiting

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

202620272028

N/A
Yeast Protein Supplementation and Muscle Preservation During GLP-1RA-Induced Weight Loss
NCT07817823
est. 20 Sept 2026 to est. 30 May 2027

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The goal of this clinical trial is to evaluate whether yeast protein supplementation can help preserve lean body mass and muscle function in adults with overweight or obesity receiving GLP-1 receptor agonist-related treatment for weight loss. The main questions it aims to answer are: 1. Does yeast protein supplementation reduce the loss of lean body mass during GLP-1RA-related weight loss? 2. Does yeast protein supplementation improve or preserve muscle function? 3. Does yeast protein supplementation affect metabolic status, inflammation, gut barrier function, gut microbiota, and related metabolites? Researchers will compare yeast protein with whey protein and a yeast protein/whey protein blend to evaluate the effects of different protein sources on muscle-related outcomes during GLP-1RA treatment. Participants will: 1. Take the assigned study product every day for 12 weeks, approximately 20 g per day. 2. Return used study-product sachets every 4 weeks so that adherence can be assessed and the next supply can be provided. 3. Attend study visits at baseline, week 4, and week 12 for questionnaire surveys, physical measurements, body composition assessment by DXA, muscle function tests, dietary assessment, and blood sampling. 4. Complete a simplified follow-up at week 8 to record GLP-1RA use and dose changes, study-product adherence, adverse events, and major changes in diet or physical activity. 5. Complete sleep assessment using a wearable sleep-monitoring device and the Pittsburgh Sleep Quality Index at baseline and week 12. 6. Provide stool samples at baseline and week 12 for assessment of gut microbiota and related metabolites.

Interventions

Yeast ProteinDietary supplement
Whey ProteinDietary supplement
Yeast Protein/Whey Protein Blend (1:1)Dietary supplement

Arms4

Experimental
Yeast Protein Group
Active comparator
Whey Protein Group
Experimental
Yeast Protein/Whey Protein Blend Group
No intervention
Blank Control Group
Participants receive no study protein product and continue their usual diet and clinically prescribed GLP-1RA treatment.

Primary outcomes1

Outcomes the sponsor listed as primary.

Change in Lean Body Mass From Baseline to Week 12
Time frame · Baseline and Week 12
Registry description
Lean body mass will be measured using dual-energy X-ray absorptiometry (DXA). The primary outcome is the change in whole-body lean body mass, expressed in kilograms (kg), from baseline to week 12. A higher or lower change indicates the degree of preservation or loss of lean body mass during GLP-1RA treatment.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies2

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Meta-analysis (pooled) · 2026

5 results

Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

Eisa et al. 2026Diabetes, obesity & metabolismcited by 3

PMID 41877354DOI 10.1111/dom.70666PUB-41877354

Full text at the publisher5 results

Publisher page See results (5)

More studies

1 study on this page

PubMed tag: none · 2026

Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study.

Alissou et al. 2026Diabetes, obesity & metabolismcited by 38

PMID 41068996PMC12673431DOI 10.1111/dom.70141PUB-41068996

CC BY

Download PDF

Other registry references

References listed at the registry that are not in PepBank. They link to PubMed.

ResultLustgarten MS. The Role of the Gut Microbiome on Skeletal Muscle Mass and Physical Function: 2019 Update. Front Physiol. 2019 Nov 26;10:1435. doi: 10.3389/fphys.2019.01435. eCollection 2019. PMID 31911785
ResultLiang Y, Liu Q, Zhang X, Li B, Hou T. Multi-omics-guided discovery: yeast protein alleviates glucocorticoid-induced muscle atrophy through dual activation of IGF-1/PI3K/Akt/FOXO and CaMKK/AMPK signaling pathways. Food Funct. 2026 Feb 23;17(4):1857-1875. doi: 10.1039/d5fo04912a. PMID 41612951
ResultMiller PE, Alexander DD, Perez V. Effects of whey protein and resistance exercise on body composition: a meta-analysis of randomized controlled trials. J Am Coll Nutr. 2014;33(2):163-75. doi: 10.1080/07315724.2013.875365. PMID 24724774

Eligibility

Who could join, as posted.

Sex: All
Age: from 25 Years up to 50 Years
Healthy volunteers: Not accepted

Inclusion and exclusion criteria, as posted

Inclusion Criteria: * Adults aged 25-50 years with overweight or obesity, defined as BMI ≥24.0 kg/m², who meet the clinical indication for GLP-1RA-related weight-loss treatment. Planning to initiate GLP-1RA treatment, or having initiated GLP-1RA treatment within the previous 4 weeks, and intending to continue treatment for at least 12 weeks. Able and willing to provide written informed consent and comply with the 12-week intervention, follow-up visits, dietary assessments, body composition measurements, muscle function tests, and biological sample collection. Exclusion Criteria: * Known allergy or intolerance to yeast protein, whey protein, milk-derived ingredients, or other components of the study products. Unable to undergo dual-energy X-ray absorptiometry (DXA) or having a contraindication to DXA examination. Sarcopenia at baseline, defined by appendicular skeletal muscle mass index (ASMI) \<7.0 kg/m² in men or \<5.4 kg/m² in women. Severe cardiovascular or cerebrovascular disease, hepatic or renal insufficiency, malignancy, or other diseases that may substantially affect skeletal muscle metabolism. Regular use of protein powder or additional protein supplementation equivalent to ≥0.3 g/kg body weight per day. Initiation or dose adjustment of statins within the previous 3 months, or a history of statin-associated myopathy. Current participation in another weight-loss program or clinical intervention trial. Long-term use of systemic glucocorticoids, anabolic agents, or other medications that may substantially affect protein or skeletal muscle metabolism. Use of other weight-loss medications, fat-loss supplements, or muscle-enhancing products within the previous 3 months, apart from the prespecified GLP-1RA-related treatment. Use of antibiotics, probiotics, prebiotics, or other products or medications likely to substantially affect the gut microbiota within the previous 1 month.

PepBank is a research reference. Talk to a doctor before you use any peptide.